Calcium Channels & Calcium Channel Antagonists
Ann Neurol 21:317-330, Greenberg,D.A., 1987
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
HIV-Related Movement Disorders, Epidemiology, Pathogenesis and Management
CNS Drugs 16:663-668, Cardoso,F., 2002
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Recovery From Experimental Parkinsonism in Primates with GM1 Ganglioside Treatment
Science 256:843-846, Schneider,J.S.,et al, 1992
Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by MPTP
NEJM 327:1556-1563, 15891992., Widner,H.,et al, 1992
Clozapine in the Treatment of Parkinsonian Patients with Dopaminomimetic Psychosis
Neurol 40:832-834, Wolters,E.Ch.,et al, 1990
Tetrabenazine Therapy of Dystonia, Chorea, Tics, & Other Dyskinesias
Neurol 38:391-394, Jankovic,J.&Orman,J., 1988
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986